12 important studies from ASH you may have missed
Click Here to Manage Email Alerts
This year’s virtual ASH Annual Meeting and Exposition featured hundreds of abstracts that spotlighted research advances in blood cancer and benign hematology research.
Healio and HemOnc Today present this recap of 12 impactful studies presented at this year’s conference.
• The addition of tranexamic acid prophylaxis to platelet transfusion did not reduce bleeding among patients with blood cancers and severe thrombocytopenia. Read more.
• The use of gene-edited stem cells has shown early positive results among patients with sickle cell disease and transfusion-dependent beta-thalassemia. Read more.
• Black young adults with favorable molecular-risk acute myeloid leukemia had poorer survival outcomes than their white counterparts. Read more.
• Patients acquired myeloproliferative neoplasm driver mutations early in life, often in utero, which then expanded at variable rates over their lifetime before diagnosis. Read more.
• The addition of mycophenolate to standard first-line steroid treatment appeared effective for patients with newly diagnosed immune thrombocytopenia. Read more.
• Asciminib (ABL001, Novartis) appeared to be more effective than bosutinib (Bosulif, Pfizer) for certain patients with chronic-phase chronic myeloid leukemia who had been treated with at least two tyrosine kinase inhibitors. Read more.
• The gene therapy etranacogene dezaparvovec (AMT-061; uniQure/CSL Behring) conferred a substantial decrease in bleeding events among patients with moderate or severe hemophilia B. Read more.
• An investigational chimeric antigen receptor T-cell therapy manufactured in less than 24 hours showed antitumor activity among patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Read more.
• Adults with AML with IDH mutations appeared to be at increased risk for coronary artery disease and exacerbated cardiotoxicity during treatment with anthracyclines. Read more.
• Researchers have identified CD58 status as a predictive marker for durable responses to CD19-directed chimeric antigen receptor T-cell therapy among patients with large B-cell lymphoma. Read more.
• Belumosudil (KD025, Kadmon Holdings) conferred high overall response rates at two dose levels among patients with chronic graft-versus-host disease. Read more.
• Certain patients with hematologic malignancies and COVID-19 appeared at higher risk for severe infection and death, according to an analysis of data from an international registry. The risk for death appeared highest among those who were older, had more severe infection, opted to forego more intensive treatment and/or had a poorer cancer prognosis before COVID-19 infection. Read more.
Collapse
Healio Coverage
Click Here to Manage Email Alerts